Prevalence and clinical characteristics of autoimmune liver disease in hospitalized patients with cirrhosis and acute decompensation in China
Zi-Xuan Shen(Shanghai Jiao Tong University), Hai Li(Shanghai Jiao Tong University), Yubao Zheng(Sun Yat-sen University), Huadong Yan(Zhejiang Shuren University), Wei Yuan(Shanghai Public Health Clinical Center), Guohong Deng(University of Groningen), Jianyi Wei(Shanghai Jiao Tong University), Xinyi Zhou(Shanghai Medical College of Fudan University), Xiaobo Lu(Xinjiang Medical University), Zhongji Meng(Hubei University of Medicine), Yanhang Gao(Jilin University), Wenting Tan(Army Medical University), Yixin Hou(Wuhan National Laboratory for Optoelectronics), Zebing Huang(Central South University), Xiong Ma(Shanghai Jiao Tong University), Beiling Li(Key Laboratory of Guangdong Province), Xin Zheng(Union Hospital), Jie Xia(Fudan University), Congcong Zou(Wuhan Union Hospital), Zhiping Qian(Shanghai Public Health Clinical Center), Sen Luo(Hubei University of Medicine), Jing Li(National Clinical Research Center for Digestive Diseases), Qun Zhang(Beijing Ditan Hospital), Chunyan Liu(Jilin University), Feng Liu(Peking University), Yuanyuan Chen(Jahra Hospital), Tao Li(Army Medical University), Yan Zhang(Sichuan Provincial Hospital of Traditional Chinese Medicine), Yan Xiong(University of Science and Technology Liaoning), Wen Gu(University Hospital Münster), Na Gao, Xianbo Wang(Capital Medical University), Jinjun Chen(Southern Medical University), Dandan Wu(Fujian Medical University), Yan Huang(Central South University), Xiuhua Jiang(Key Laboratory of Guangdong Province), Jun Chen(Shanghai Jiao Tong University), Jia Shang(European Foundation for the Study of Chronic Liver Failure)
Cited by 12
Related Papers
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study
|Chinese Medical Journal|2020|1.4k
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
|The Lancet Oncology|2019|649
Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer
|European Urology|2019|464
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
|Cancer Discovery|2017|422